PCA50941

Cat. No.:	HY-U00034
CAS No.:	136941-85-0
Molecular Formula:	$C_{30}H_{31}N_3O_{10}S$
Molecular Weight:	625.65
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PCA50941 is a 1,4-dihydropyridine derivative, used for treatment for cardiovascular disease.
In Vitro	PCA50941 (1 μM) shifts the I-V relationship of whole-cell Ca^{2+} currents by about 5-10 mV towards more hyperpolarizing potentials. PCA50941 increases further the K(+)-evoked peak to 655 nM. In the presence of 5 mM Ca^{2+}, PCA50941 increases the [Ca^{2+}] peaks to 427 nM. PCA50941 potentiates the release of catecholamines from perfused bovine adrenal glands evoked by 30 s pulses of 17.7 mM K^+ in a manner dependent on the [Ca^{2+}]o[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	PCA50941 (10-120 μM) by intracoronary injection, causes smaller reductions of coronary blood flow (CBF) in goats. PCA50941 (10-300 μM/min) does not modify CBF nor the other hemodynamic variables recorded by i.v. infusions in 4 goats. Intravenous infusion of PCA50941 (100 microg/min) reverses the hemodynamic variables from the shock state to control values within 20 min in 5 of 6 animals[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Montiel C, et al. Interactions between Ca2+, PCA50941 and Bay K 8644 in bovine chromaffin cells. Eur J Pharmacol. 1994 Aug 16;268(3):293-303.

[2]. Fernández N, et al. PCA50941, a new 1,4-dihydropyridine, reverses endothelin-induced cardiogenic shock in the anesthetized goat. Life Sci. 1998;62(21):1933-42.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA